Patent US4795644A successfully refreshed from Google Patents.
US4795644A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
Assignee: Merck and Co Inc
•
Filing: 1987-08-03
•
Granted: 1989-01-03
•
Expires: 2007-08-03
Abstract
Abstract A device is disclosed for the controlled delivery of a beneficial agent. The agent is delivered to the environment surrounding the device at a substantially constant rate for a specified period with a reduced dependence on the environmental pH. The device is comprised of a core compartment containing (1) a charged, water insoluble, non-diffusible component and (2) at least one diffusable water soluble ionizable beneficial agent. The core is surrounded by a water insoluble wall containing leachable pore forming additive(s) dispersed throughout said wall, with said wall impermeable to core components (1) and permeable to beneficial agent(s) (2). In operation the insoluble charged component (often polymeric resins) and water soluble ionizable beneficial agent have the same electro-static charge and do not form an ion exchange complex. Rather, a Donnan influenced mass transport phenomena of the beneficial agent is effected through the pores in the device, actuated by water from the environment, with migration of the freely mobile diffusible species (beneficial agent) away from the non-mobile species (charged entity). This effects the release of the beneficial agent through the wall at a controlled rate with reduced pH dependency.
Inventors
- 👤 Gaylen M. Zentner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 11:33
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
106 words
A drug-delivery device for the controlled release of a therapeutically active ingredient into an environment of use which comprises: (A) a core composition comprising (a) a water insoluble, non-diffusible charged resin entity, and (b) a diffusible water soluble ionizable therapeutically active ingredient carrying the same charge as said resin entity; and (B) a water insoluble wall surrounding said core composition and prepared from (i) a polymer material that is permeable to water but substantially impermeable to solute and (ii) 0.1 to 75% by weight, based on the total weight of (i) and (ii), of at least one water leachable pore forming additive dispersed throughout said wall.
Claim 2
Dependent Claim
106 words
A drug-delivery device for the controlled release of a therapeutically active ingredient into an environment of use which comprises: (A) a core composition comprising (a) a water insoluble, non-diffusible charged resin entity, and (b) a diffusible water soluble ionizable therapeutically active ingredient carrying the same charge as said resin entity; and (B) a water insoluble wall surrounding said core composition and prepared from (i) a polymer material that is permeable to water but substantially impermeable to solute and (ii) 0.1 to 75% by weight, based on the total weight of (i) and (ii), of at least one water leachable pore forming additive dispersed throughout said wall.
Claim 3
Dependent Claim
50 words
A drug-delivery device according to claim 1, wherein the resin entity is a cationic resin selected from the group consisting of polystyrene, epoxy-amine, phenolic or condensate polymeric backbones containing an active group of quaternary ammonium, secondary amine, tertiary amine in an aromatic matrix or tertiary amine in an aliphatic matrix.
Claim 4
Dependent Claim
30 words
A drug-delivery device according to claim 1, wherein the resin entity is n anionic resin with acrylic, methacrylic or phenolic polymeric backbones with phosphonic acid or carboxylic acid active groups.
Claim 5
Dependent Claim
28 words
A drug-delivery device according to claim 1, wherein the resin entity is an anionic resin with polystyrene or phenolic polymeric backbones containing an active group of sulfonic acid.
Claim 6
Dependent Claim
32 words
A drug-delivery device according to claim 1, wherein the resin entity is a cellulose polymer selected from the group consisting of diethylaminoethyl cellulose, carboxymethyl cellulose, guanidoethyl cellulose, sulfoethyl cellulose, and sulfopropyl cellulose.
Claim 7
Dependent Claim
17 words
A drug-delivery device according to claim 1, wherein the resin entity is a cross-linked vinyl pyridine polymer.
Claim 8
Dependent Claim
31 words
A drug-delivery device according to claim 1, wherein the therapeutically active ingredient is soluble in an external fluid and exhibits an osmotic pressure gradient across the wall against the external fluid.
Claim 9
Dependent Claim
46 words
A drug-delivery device according to claim 1, wherein the therapeutically active ingredient has limited solubility in the external fluid and is mixed with an osmotically effective solute that is soluble in the fluid, which exhibit an osmotic pressure gradient across the wall against the external fluid.
Claim 10
Dependent Claim
28 words
A drug-delivery device according to claim 8, which further comprises in the core a member selected from water soluble excipients, buffers, insoluble buffers, bulking agents, and osmotic regulators.
Claim 11
Dependent Claim
61 words
A drug-delivery device according to claim 1, wherein said pore forming additive comprises: (a) 0.1 to 50%, by weight, solid additive, based on the total weight of (i) and (ii), and/or (b) 0.1 to 40%, by weight, liquid additive, based on the total weight of (i) and (ii), not to exceed a total weight % of pore forming additive of 60%.
Claim 12
Dependent Claim
20 words
A drug-delivery device according to claim 10, wherein 0.1 to 50%, by weight, of said pore forming additive is used.
Claim 13
Dependent Claim
36 words
A drug-delivery device according to claim 11, wherein said pore forming additive is selected from the group consisting of water, alkali metal salts, alkaline earth metal salts, saccharides, aliphatic polyols, aromatic polyols, nicotinamide and mixtures thereof.
Claim 14
Dependent Claim
26 words
A drug-delivery device according to claim 12, wherein said pore forming additive is selected from the group consisting of polyethylene glycol, sorbitol, glucose and mixtures thereof.
Claim 15
Dependent Claim
43 words
A drug-delivery device according to claim 1, further comprising: (C) 0 to 50 parts per 100 parts of (i) and (ii) of plasticizer and flux regulating additives and (D) 0 to 40 parts per 100 parts of (i) and (ii), of surfactant additive.
Claim 16
Dependent Claim
37 words
A drug-delivery device according to claim 1, wherein said water insoluble wall is 1 to 1,000 microns thick and wherein 5 to 95% of the resulting wall pores are between 10 angstroms and 100 microns in diameter.
Claim 17
Dependent Claim
29 words
A drug-delivery device according to claim 15 wherein said wall is 20 to 500 microns thick and said wall pores are between 10 angstroms and 25 microns in diameter.
Claim 18
Dependent Claim
17 words
A drug-delivery device according to claim 1, wherein at least 0.05 ng of active agent are used.
Claim 19
Dependent Claim
17 words
A drug-delivery device according to claim 17, wherein at least 1 microgram of active agent is used.
Claim 20
Dependent Claim
37 words
A drug-delivery device according to claim 1, wherein said polymer is selected from the group consisting of cellulose esters, acylated polysaccharides, polyurethane, polymers of acrylic and methacrylic acid and esters thereof, poly(ortho ester)s, polyacetals and mixtures thereof.
Claim 21
Dependent Claim
22 words
A drug-delivery device according to claim 19, wherein said polymer is selected from the group consisting of cellulose esters and acylated polysaccharides.
Claim 22
Dependent Claim
28 words
A drug-delivery device according to claim 20, wherein said polymer is selected from the group consisting of polyurethanes and polymers of acrylic and methacrylic acid and esters thereof.
Claim 23
Dependent Claim
21 words
A drug-delivery device according to claim 20, wherein said polymer is selected from the group consisting of poly(ortho ester)s and polyacetals.
References Cited (Backward Citations)
US2846057A
Cited
US2928770A
Cited
US3538214A
Cited
US4244941A
Cited
US3957523A
Cited
US3993072A
Cited
US4160452A
Cited
US4256108A
Cited
US4200098A
Cited
US4217898A
Cited
US4285987A
Cited
US4221778A
Cited
US4235236A
Cited
US4309996A
Cited
US4320759A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-01-03 | 1992-07-04 | 1993-01-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-01-03 | 1996-07-04 | 1997-01-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-01-03 | 2000-07-04 | 2001-01-03 | $7700.00 | Window Closed / Lapsed |